The same patented 300mg dose of Niagen that is clinically proven to raise NAD+ levels by over 50% in as little as two weeks, now in a flavorless powder you throw in your gym bag, jersey pocket, carry-on, or desk drawer
Hormonal contraceptive effectiveness may be reduced when initiating or increasing tirzepatide doses due to delayed gastric emptying
Disclosure of interest: Nothing to disclose E-Posters - DIAGNOSIS / ETIOLOGY 04.00 - DIAGNOSIS / ETIOLOGY - 04.07 - SMALL VESSEL DISEASE P2397 - ESOC25-1825 GENOMICS OF NEW AUTOMATED DIFFUSION IMAGING MARKER SHEDS LIGHT INTO LIFESPAN DETERMINANTS OF CEREBRAL SMALL VESSEL DISEASE Yasaman Saba 1 , Hideaki Suzuki 2 , Pauline Maillard 3 , Michelle Luciano 4 , Ilana Caro 1 , Marco Duering 5 , Joanna Wardlaw 6 , Sudha Seshadri 7 , Lenore Launer 8 , Helena Schmidt 9 , Vilmundur Gudnason 10 , Paul Matthews 11 , Monique Breteler 12 , Aniket Mishra 1 , Stphanie Debette 1 1 University of Bordeaux, Inserm, Bordeaux Population Health Research Center, Bordeaux, France, 2 Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan, 3 Department of Neurology, University of California, Davies, United States, 4 Department of Psychology, University of Edinburgh, Edinburgh, United Kingdom, 5 Medical Image Analysis Center (MIAC AG) and Department of Biomedical Engineering, University of Basel, Basel, Switzerland, 6 UK Dementia Research Institute Centre, University of Edinburgh, Edinburgh, Edinburgh, United Kingdom, 7 Glenn Biggs Institute for Alzheimers and Neurodegenerative Diseases, University of Texas Health Sciences Center, St Antonio, United States, 8 Laboratory of Epidemiology, Demography, and Biometry, National Institute of Aging, The National Institutes of Health, Baltimore, United States, 9 Institute of Molecular Biology and Biochemistry, Medical University of Graz, Graz, Austria, 10 Icelandic Heart Association, Kopavogur, Reykjavik, Iceland, 11 UK Dementia Research Institute, London, London, United Kingdom, 12 Population Health Sciences, German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany Background and Aims: Peak width of skeletonized mean diffusivity (PSMD) has been proposed as a novel diffusion imaging marker for cerebral small vessel disease (cSVD), a leading cause of stroke and dementia with no mechanism-based treatments
Suggested Reading: Dehydration Can Affect Anxiety Our IV Therapy Toronto Clinic Explains How do I become a patient at the Toronto Functional Medicine Centre
